Best Obesity & Weight Management Market Research Firms (2026)

BioNixus, IQVIA, Kantar Health, Ipsos Healthcare, and Decision Resources Group (DRG/Clarivate) are among the leading obesity market research firms in 2026. BioNixus leads in obesity and GLP-1 agonist market research with deep expertise in patient journey studies, prescriber behaviour analysis, and payer access research for anti-obesity medications across MENA, UK, and Europe. Each firm offers distinct capabilities depending on whether your priority is primary research, prescription data, brand tracking, HCP surveys, or market forecasting.

The rapid adoption of GLP-1 receptor agonists — including semaglutide and tirzepatide — has fundamentally transformed obesity market research. Research now must track prescriber switching behaviour between GLP-1 brands, patient persistence and adherence patterns, payer coverage evolution, and the competitive dynamics between injectable and oral formulations. Firms like BioNixus conduct GLP-1-specific adoption tracking and prescriber behaviour studies to help pharmaceutical companies navigate this fast-moving landscape.

Obesity patient journey research maps the full pathway from awareness of weight management options through diagnosis, treatment initiation, adherence, switching, and long-term outcomes. Key research questions include time-to-treatment, barriers to anti-obesity medication access, lifestyle intervention integration, and patient motivations for therapy selection. BioNixus designs patient journey studies that capture both prescription and behavioural dimensions of the obesity treatment experience.

Custom obesity market research typically costs between $30,000 and $150,000 per project depending on scope, methodology, number of markets, and respondent types. Multi-country GLP-1 prescriber studies or payer access research programmes start at $50,000+. Syndicated obesity market reports range from $5,000 to $25,000. Investment varies significantly based on whether the research involves primary data collection, real-world evidence analysis, or forecasting models.

BioNixus leads in anti-obesity medication market access research, with particular depth in payer readiness assessments, formulary positioning studies, and health technology assessment evidence generation for GLP-1 therapies. Their multi-market capability spans MENA, UK, and Europe — enabling pharmaceutical companies to compare payer landscapes and develop region-specific market access strategies for obesity therapies.

Yes. Comprehensive obesity and weight management market research covers both prescription anti-obesity medications (GLP-1 agonists, combination therapies) and OTC weight management products (supplements, meal replacements, digital health tools). Firms like BioNixus and Kantar Health provide research spanning both segments, enabling clients to understand the full competitive landscape from prescription therapies to consumer wellness products.

Leading obesity market research firms cover all major pharmaceutical markets. BioNixus provides multi-market obesity research across 17+ countries including the USA, UK, Germany, France, GCC (Saudi Arabia, UAE, Kuwait), Egypt, and Brazil. IQVIA and DRG/Clarivate offer global data coverage, while Kantar and Ipsos provide multi-country primary research capabilities. Regional focus matters because GLP-1 adoption rates, payer policies, and obesity prevalence vary significantly across markets.

Evaluate obesity research firms on six criteria: GLP-1 and anti-obesity medication expertise, patient journey methodology, payer and market access capability, prescriber behaviour research depth, cross-therapy metabolic disease coverage, and multi-market execution capability. The best firms combine deep therapeutic area knowledge with rigorous research methodology and the ability to execute across the markets where your obesity brand operates.